Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07531745) titled 'ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome' on April 8.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Ionis Pharmaceuticals, Inc.

Condition: Dravet Syndrome

Intervention: Drug: ION337

Recruitment Status: Not recruiting

Phase: Phase 1/Phase 2

Date of First Enrollment: April 2026

Target Sample Size: 32

To know more, visit https://clinicaltrials.gov/study/NCT07531745

Disclaimer: Curated by HT Syndication....